<DOC>
	<DOCNO>NCT00947440</DOCNO>
	<brief_summary>The purpose study assess bioavailability , safety , tolerability pharmacokinetics two tablet formulation compare capsule formulation suspend liquid .</brief_summary>
	<brief_title>Evaluation Bioavailability Two ABT-072 Tablet Formulations Compared ABT-072 Capsule Formulation</brief_title>
	<detailed_description>A single-dose , three period , complete cross-over study evaluate relative bioavailability , pharmacokinetics , safety tolerability two candidate tablet formulation ABT-072 compare original capsule formulation suspend liquid reference .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Overall healthy subject , nonchildbearing female include . Use medication ( prescription overthecounter ) , vitamin , herbal supplement within 2week period prior first dose study drug administration within 10 halflives respective medication , whichever longer . Pregnant breastfeed female . Positive test result hepatitis A virus immunoglobulin M ( HAVIgM ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) , HIV antibody ( HIV Ab ) . Positive screen drug abuse , alcohol , cotinine . Clinically significant cardiovascular , respiratory ( except mild asthma ) , renal , gastrointestinal , hematologic , neurologic , thyroid , uncontrolled medical illness psychiatric disorder . Use tobacco nicotinecontaining product within 6month period precede study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Bioavailability</keyword>
</DOC>